1,3-dimethyl-N-[[1-[(4-methylpiperazin-1-yl)methyl]cyclopropyl]methyl]-2,6-dioxopyrimidine-4-carboxamide
C17H27N5O3 — CID 118779324
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1,3-dimethyl-N-[[1-[(4-methylpiperazin-1-yl)methyl]cyclopropyl]methyl]-2,6-dioxopyrimidine-4-carboxamide
1,3-dimethyl-N-[[1-[(4-methylpiperazin-1-yl)methyl]cyclopropyl]methyl]-2,6-dioxopyrimidine-4-carboxamide (PubChem CID 118779324) has the molecular formula C17H27N5O3 and a molecular weight of 349.44 g/mol. Its IUPAC name is 1,3-dimethyl-N-[[1-[(4-methylpiperazin-1-yl)methyl]cyclopropyl]methyl]-2,6-dioxopyrimidine-4-carboxamide.
Molecular Properties
| Compound Name | 1,3-dimethyl-N-[[1-[(4-methylpiperazin-1-yl)methyl]cyclopropyl]methyl]-2,6-dioxopyrimidine-4-carboxamide |
|---|---|
| PubChem CID | 118779324 |
| Molecular Formula | C17H27N5O3 |
| Molecular Weight | 349.44 g/mol |
| Exact Mass | 349.21 |
| IUPAC Name | 1,3-dimethyl-N-[[1-[(4-methylpiperazin-1-yl)methyl]cyclopropyl]methyl]-2,6-dioxopyrimidine-4-carboxamide |
| SMILES | CN1CCN(CC2(CNC(=O)c3cc(=O)n(C)c(=O)n3C)CC2)CC1 |
| InChI | InChI=1S/C17H27N5O3/c1-19-6-8-22(9-7-19)12-17(4-5-17)11-18-15(24)13-10-14(23)21(3)16(25)20(13)2/h10H,4-9,11-12H2,1-3H3,(H,18,24) |
| InChIKey | QJXQKDHXCFYQBO-UHFFFAOYSA-N |
| XLogP | -1.16 |
| TPSA | 79.58 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 25 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 349.44 |
| LogP ≤ 5 | -1.16 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 118779324 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.